STERIS Q2 revenue up 10% to $1.5 billion; EPS $1.94; outlook raised
STERIS reported fiscal 2026 second-quarter results for the quarter ended September 30, 2025, with revenue from continuing operations up 10% to $1.5 billion and diluted EPS from continuing operations rising to $1.94 from $1.51 a year earlier. The company raised its fiscal 2026 adjusted EPS outlook to $10.15 to $10.30 and its free cash flow expectation to about $850 million, which points to higher expected per-share earnings and cash generation for shareholders.
Key points
- Q2 revenue from continuing operations rose to $1,460.3 million from $1,328.9 million; constant currency organic growth was 9%.
- Diluted EPS from continuing operations was $1.94 vs. $1.51; adjusted EPS was $2.47 vs. $2.14.
- Fiscal 2026 adjusted EPS outlook raised to $10.15 to $10.30 from $9.90 to $10.15; free cash flow expected at about $850 million vs. $820 million prior.
- Tariffs are estimated to reduce pre-tax profit by about $45 million, unchanged from prior outlook.
The filing
Written by AI on Nov 8, 2026, 1:10 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on November 05, 2025.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.